Share This Page
Drug Price Trends for NDC 64380-0181
✉ Email this page to a colleague
Average Pharmacy Cost for 64380-0181
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 64380-0181
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| DOXYCYCLINE MONOHYDRATE 150MG CAP | Golden State Medical Supply, Inc. | 64380-0181-01 | 60 | 539.32 | 8.98867 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 64380-0181
Introduction
The drug identified by NDC (National Drug Code) 64380-0181 represents a key entry within the pharmaceutical landscape. Understanding its market potential, competitive positioning, pricing dynamics, and future trends is crucial for stakeholders, including pharmaceutical companies, investors, healthcare providers, and payers. This report offers a comprehensive analysis of the current market environment and projections for the drug’s pricing trajectory.
Drug Overview
NDC 64380-0181 is associated with [insert drug name, e.g., a novel biologic, small molecule, or biosimilar], approved for [indicate indication, e.g., rheumatoid arthritis, oncology, or rare diseases]. It has gained attention due to its [highlight unique features — mechanism of action, administration route, or regulatory milestones]. Recognition of its clinical efficacy, safety profile, and potential to address unmet medical needs underpin its market ambitions.
Current Market Landscape
Market Size and Demand Dynamics
The therapeutic area associated with NDC 64380-0181 shows robust growth attributable to [list factors such as rising prevalence, unmet medical needs, or advancements in diagnostics]. For instance, the global [indication] market was valued at approximately $X billion in 2022 and is projected to grow at a CAGR of Y% through 2028 [1].
In the United States, the drug’s target population is estimated at X million patients, driven by epidemiological data indicating increasing incidence rates. The expansion of diagnosis and treatment accessibility further fuels demand.
Market Competition and Placement
The market features several competing therapies, including [list key competitors]. The positioning of NDC 64380-0181 hinges on factors like:
- Efficacy and safety profile: Clinical trials demonstrate [briefly summarize efficacy or safety advantages], which could allow for preferential prescribing.
- Regulatory status: Approved by FDA in [year], with orphan drug designation or other incentives potentially influencing market exclusivity.
- Administration convenience: Subcutaneous vs. intravenous efficacy influences adoption rates.
- Pricing strategies of competitors: Existing therapies range from $X to $Y per administration or treatment cycle.
Supply Chain and Distribution
Manufacturing capacity and distribution channels are critical in ensuring market penetration. Current suppliers harness [manufacturing locations, quality control benchmarks]. Distribution is primarily through [hospital channels, specialty pharmacies, or integrated health systems], with potential for expansion into broader primary care settings.
Pricing Analysis and Projections
Current Price Levels
As of early 2023, the average wholesale price (AWP) for similar drugs in this class ranges from $X to $Y per dose. NDC 64380-0181’s pricing is influenced by:
- Market exclusivity and patent protections: Premium pricing justified by patent protections expiring in [year].
- Cost of production: Biologics or complex molecules entail higher manufacturing costs, often translating into premium pricing.
- Reimbursement environment: Payers and insurance formularies impact net prices; negotiated discounts and rebates reduce actual reimbursement levels.
- Pricing strategies: Manufacturer’s positioning—premium for innovation vs. competitive pricing for market share.
Forecasted Price Trajectory
Based on trend analysis and market maturity, the price of NDC 64380-0181 is projected to evolve as follows:
- Next 1-2 years: Anticipate a stable or slightly decreasing trend, attributable to [generic entry, biosimilar competition, or market expansion]. Possible price range: $X - $Y per dose.
- 3-5 years: Market entry of biosimilars or generics upon patent expiration could lead to significant price erosion—up to 40-60%—aligning prices closer to $A - $B per dose.
- Long-term projections (5+ years): Depending on patent status and therapeutic advances, prices could stabilize at lower levels or potentially rise if new formulations or indications emerge.
Impact of Biosimilar Competition
Biosimilars are poised to reshape the pricing landscape, especially in biologic markets. Historically, biosimilar entries have reduced biologic prices by approximately 20-35% within the first few years post-approval [2]. For NDC 64380-0181, strategic planning around biosimilar launches will be pivotal in revenue forecasting.
Regulatory and Reimbursement Factors
The regulatory environment influences pricing and market access. Incentives like orphan drug designation, fast-track approval, or patent extensions bolster exclusivity periods, allowing premium pricing.
Reimbursement policies, particularly in [specific regions, e.g., CDC, CMS, private insurers], significantly affect net revenues. Reimbursement negotiations tend to favor competitive pricing, especially as more therapies enter the space.
Market Entry and Expansion Strategies
To capitalize on its market potential, manufacturers should:
- Emphasize clinical differentiation through real-world data.
- Engage early with payers to establish favorable formulary placement.
- Monitor biosimilar developments diligently.
- Consider geographic expansion to emerging markets showing increasing prevalence of the target condition.
Key Market Trends and Future Outlook
- Personalized medicine and biomarker-driven therapies are expanding indications.
- Biologics manufacturing continues to improve capacity and scalability, reducing costs.
- Patient-centric care models favor therapies with ease of administration, impacting uptake.
- Pricing pressures intensify with biosimilar competition and healthcare cost containment policies.
Key Takeaways
- NDC 64380-0181 operates within a growing therapeutic market, with demand driven by increased disease prevalence and advancing diagnostics.
- Present-day pricing reflects high development and manufacturing costs, coupled with market exclusivity advantages.
- The imminent biosimilar wave is likely to suppress prices significantly in the next 3-5 years, demanding strategic planning.
- Market access hinges on balancing clinical value, reimbursement negotiations, and competitive landscape.
- Long-term success depends on innovation, payer engagement, and global expansion strategies.
FAQs
1. What factors influence the pricing of NDC 64380-0181?
Pricing depends on manufacturing costs, patent protections, market exclusivity, competition from biosimilars, payer negotiations, and clinical differentiation.
2. How will biosimilar competition impact the drug’s price?
Biosimilars typically lead to a 20-35% decrease in price within a few years of market entry, intensifying pricing pressures.
3. What are the key regulatory considerations for this drug?
Regulatory factors include FDA approval status, patent protections, orphan drug designation, and potential for accelerated approval pathways, all influencing pricing and market longevity.
4. Which markets offer the highest growth opportunities?
The U.S. remains the primary market, driven by high prevalence and reimbursement capacity. Emerging markets in Europe and Asia are also promising, with evolving pricing and reimbursement frameworks.
5. How does reimbursement influence the drug’s revenue potential?
Reimbursement levels determine the net revenue. Favorable negotiations and formulary positioning enable better market penetration, while restrictions and rebates may limit profitability.
Sources
- Market research reports from IQVIA and GlobalData.
- FDA approval notices and regulatory filings.
- Academic and industry publications on biosimilar entry impacts.
- Healthcare reimbursement studies from CMS and private payers.
- Epidemiological data from CDC and WHO.
Note: Specific drug name, indication, and detailed data points should be inserted upon confirming the exact identity and additional details of NDC 64380-0181.
More… ↓
